Orchard Therapeutics
London, GB · Founded 2018 · Incorporated in United Kingdom · 239 employees on LinkedIn · 8 known investors
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy. The Nasdaq-listed biotech (ticker ORTX) has commercialized therapies including Strimvelis and Libmeldy in Europe.
Founders & leadership
Orchard Therapeutics was founded in 2018 by Donald Kohn and Adrian Thrasher.
DK
Donald KohnScientific Founder
AT
Adrian ThrasherScientific Founder
FE
Frank E. ThomasinPresident & Chief Operating OfficerFrank E. Thomas is an executive in the life sciences sector with experience leading biotech and pharmaceutical companies through development and commercialization stages, including roles at public and venture-backed firms where he was involved in raising over $2 billion in capital and executing major business development transactions.
SM
Steven M. AltschulerNamed on SEC filing
JC
John CurnutteNamed on SEC filing
Board
BG
JA
James A. GeraghtyBoard director
JT
Joanne T. BeckBoard director
MD
Marc DunoyerBoard director
AS
Alicia SecorBoard director
CR
Charles Rowland, Jr.Board director
Investors · 8
Reported raises · per SEC filings
Form D private placements$184M disclosed across 2 rounds · 2021–2023
▶$34MraisedMar 2023 · 7 investors · BiotechnologyRule 506(b)
▶$34MraisedMar 2023 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James A. GeraghtyDirector
- Joanne T. BeckDirector
- Bobby GasparExecutive Officer, Director
- Marc DunoyerDirector
- Steven M. AltschulerDirector
- Frank E. ThomasExecutive Officer
- Alicia SecorDirector
- Charles Rowland, Jr.Director
- John CurnutteDirector
- Amount sold
- $34M
- Sales commissions
- $3.2M
- Placement agents
- GUGGENHEIM SECURITIES, LLC
- First sale
- Mar 2023
- Incorporated
- Other, United Kingdom, 2018
- Federal exemptions
- 06b
▶$150MraisedFeb 2021 · 24 investors · BiotechnologyRule 506(b)
▶$150MraisedFeb 2021 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven AltschulerDirector
- Frank E. ThomasExecutive Officer
- John CurnutteDirector
- Charles Rowland Jr.Director
- Alicia SecorDirector
- Jon EllisDirector
- James A. GeraghtyDirector
- Joanne T. BeckDirector
- Bobby GasparExecutive Officer, Director
- Marc DunoyerDirector
- Offering amount
- $150M
- Amount sold
- $150M
- Sales commissions
- $6M
- Placement agents
- Oppenheimer & Co. Inc., Cantor Fitzgerald & Co., Cowen and Company, LLC
- First sale
- Feb 2021
- Incorporated
- Other, United Kingdom, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapApplied Therapeutics28 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Bioworld23 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Orchard Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Companies House · registry record
View on Companies House ↗- Registered name
- ORCHARD THERAPEUTICS LIMITED
- Company number
- 11494381
- Status
- Dissolved
- Company type
- Private limited company
- Incorporated
- 1 Aug 2018
- Dissolved
- 20 Jan 2026
- Registered office
- 245 Hammersmith Road, 3rd Floor, London, W6 8PW
- Nature of business (SIC)
- 64209 — Activities of other holding companies n.e.c.72110 — Research and experimental development on biotechnology
- Previous names
- ORCHARD THERAPEUTICS PLC (2018–2024)ORCHARD THERAPEUTICS LIMITED (2018–2018)ORCHARD RX LIMITED (2018–2018)
- Accounts
- last made up to 31 Dec 2023
- Confirmation statement
- last made up to 7 Feb 2025
Current officers
- Christopher Tappan York — secretary, appointed 28 Feb 2022
- Jonathan Henry Welbore Ellis — director, appointed 22 Feb 2024
- Yasuo Fujii — director, appointed 24 Jan 2024
- Hubert Baburaj Gaspar — director, appointed 3 Oct 2018
- Abdul Hafeez Mullick — director, appointed 24 Jan 2024
- Takeyoshi Yamashita — director, appointed 24 Jan 2024
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Orchard Therapeutics do?
- Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy. The Nasdaq-listed biotech (ticker ORTX) has commercialized therapies including Strimvelis and Libmeldy in Europe.
- Who founded Orchard Therapeutics?
- Orchard Therapeutics was founded by Donald Kohn, Adrian Thrasher in 2018.
- Who are Orchard Therapeutics's investors?
- Orchard Therapeutics's investors include AlbionVC, F-Prime Capital, Foresite Capital, UCL Technology Fund, Agent Capital, Baillie Gifford, ORI Capital, Temasek.
- How much funding has Orchard Therapeutics raised?
- Orchard Therapeutics has disclosed $184M raised across 2 rounds.
- Where is Orchard Therapeutics headquartered?
- Orchard Therapeutics is headquartered in London, GB.